Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients’ outcome?

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2023-12, Vol.37 (12), p.2517-2519
Hauptverfasser:	Bouchla, Anthi, Papageorgiou, Sotirios G., Symeonidis, Argyris, Sakellari, Ioanna, Zikos, Panagiotis, Thomopoulos, Thomas P., Hatzimichael, Eleftheria, Galanopoulos, Athanasios, Vyniou, Nora-Athina, Kotsianidis, Ioannis, Pappa, Vasiliki
Format:	Artikel
Sprache:	eng
Schlagworte:	692/499 692/699/1541/1990/1673 Antimetabolites, Antineoplastic - therapeutic use Azacitidine - therapeutic use Blood platelets Cancer Research Clinical trials Critical Care Medicine Hematology Hospitals Humans Intensive Internal Medicine Letter Leukemia Leukemia, Myeloid, Acute - drug therapy Medical prognosis Medicine Medicine & Public Health Myelodysplastic Syndromes - drug therapy Oncology Patients Remission Induction Stem cell transplantation Survival analysis Treatment Outcome Working groups
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!